Moberg

Franklin Templeton Launches Franklin Focused Growth ETF (FFOG)

Retrieved on: 
Monday, November 6, 2023
Professional Services, Finance, Intelligence, ETF, IQM, MCSE, HELX, Moberg, CBOE, Franklin, Investment, Financial adviser

Franklin Templeton today launched Franklin Focused Growth ETF on CBOE under the ticker FFOG.

Key Points: 
  • Franklin Templeton today launched Franklin Focused Growth ETF on CBOE under the ticker FFOG.
  • This ETF was converted from a mutual fund, and it maintains the predecessor Franklin Focused Growth Fund’s investment goal, principal investment strategies, performance benchmark, investment adviser and portfolio management team.
  • Moberg is also the portfolio manager of four thematic ETFs focused on dynamic innovation: Franklin Intelligent Machines ETF (IQM), Franklin Exponential Data ETF (XDAT), Franklin Disruptive Commerce ETF (BUYZ) and Franklin Genomic Advancements ETF (HELX).
  • “I am very excited to bring the Franklin Focused Growth ETF to the market.

Cipher Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
Telephone, Psoriasis, Degenerative disease, TSX, Adjustment, Plasma protein binding, Marketing, Sun, EBITDA, CDN, Food, SEDAR, Industry, Management, American, Partnership, Tax, Safety, Eflornithine, Privacy, Webcast, Rheumatoid arthritis, Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, Interim, Substance-related disorder, Growth, Hospital, Compliance, European, Income, Moberg, COVID-19, Acquisition, IFRS, Coronavirus, Tirofiban, Goal, Mission statement, Onychomycosis, FDA, Hope, Conversation, Company, Depreciation, Risk, Financial statement, Insurance, CPH, III, Adoption, Weapon, Cryptocurrency, Pharmaceutical industry, Fossil fuel, Online gambling, Mobile phone, Bookkeeping, MISSISSAUGA, Isotretinoin, IQVIA, Isotretinoin

(All figures are in U.S. dollars)

Key Points: 
  • (All figures are in U.S. dollars)
    Strong balance sheet with $24.2 million in cash at June 30, 2022
    MISSISSAUGA, ON, Aug. 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and six month periods endedJune 30, 2022.
  • Craig Mull, Interim CEO commented,"We are pleased to report that Cipher delivered another strong quarter, generating positive net income and cash from operating activities.
  • Cipher will hold a conference call onAugust 12, 2022, at8:30 a.m. (ET)to discuss its financial results and other corporate developments.
  • Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.

Cipher Pharmaceuticals Reports Strong First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
CPH, Telephone, Company, Eflornithine, Conversation, Mission statement, EBITDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Depreciation, Webcast, Sun Pharma, Moberg, Goal, Insurance, SEDAR, Tax, Coronavirus, Risk, March 31, Privacy, COVID-19, Marketing, Adjustment, TSX, Tirofiban, FDA, Hope, Industry, Sun, Substance-related disorder, Partnership, Intellectual property, Compliance, Hospital, Management, Financial statement, Onychomycosis, IFRS, Adoption, Acquisition, Growth, Interim, Degenerative disease, Weapon, Online gambling, Pharmaceutical industry, Fine chemical, Renewable energy, Mobile phone, Bookkeeping, Isotretinoin, MISSISSAUGA, IQVIA, Isotretinoin

Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."

Key Points: 
  • Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."
  • During the first quarter, Cipher announced an extension of the distribution and supply agreement with Sun Pharmaceutical Industries ("Sun Pharma") through December 31, 2026.
  • This extension will provide Cipher with an additional four years of visibility into stable revenue and cashflow on the isotretinoin portfolio.
  • Cipher will hold a conference call onMay 13, 2022, at8:30 a.m. (ET)to discuss its financial results and other corporate developments.

Cipher Pharmaceuticals Announces Partner, Moberg Pharma's Regulatory Submission to FDA for North American Phase 3 Study

Retrieved on: 
Tuesday, March 22, 2022
Adoption, Market capitalization, Company, Interim, Moberg, OMX, Marketing, Terbinafine, Substance-related disorder, Coronavirus, Compliance, Risk, Hospital, CDN, Privacy, Food, Onychomycosis, TSX, Nasdaq Stockholm, Industry, Goal, Hope, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, CRO, CPH, FDA, Insurance, Acquisition, Patient, Partnership, Pharmaceutical industry, Fine chemical, IQVIA

The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America.

Key Points: 
  • The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America.
  • The study design builds on the experience gained from the previous Phase 3 studies.
  • Moberg Pharma will cooperate with the same CRO, lead investigator and successful sites from the previous North American study.
  • "We are pleased to see the continued progress that Moberg is making to commercialize MOB-015," said Craig Mull, Interim CEO of Cipher.

Moberg Pharmas Year-end report 2020

Retrieved on: 
Tuesday, February 9, 2021
Moberg

The issue provided Moberg Pharma with proceeds of approximately SEK 150 million before transaction costs.

Key Points: 
  • The issue provided Moberg Pharma with proceeds of approximately SEK 150 million before transaction costs.
  • The BUPI project was placed in the subsidiary OncoZenge AB, which is now distributed to Moberg Pharma's shareholders and, as planned, will be separately listed on Nasdaq First North Growth Market in February 2021.
  • Moberg Pharma's primary asset is MOB-015, where preparations are underway for registration in Europe, based on two large Phase 3 studies totaling more than 800 patients.
  • Moberg Pharma's shares in OncoZenge are distributed to Moberg Pharma's shareholders according to Lex ASEA rules, where shareholders who owned shares on February 5 receive one share in OncoZenge for every ten ordinary shares they own in Moberg Pharma.

Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex Asea

Retrieved on: 
Friday, January 29, 2021
Equity securities, Stock market, Moberg, Share

Today, the Board of Moberg Pharma has decided that the record date for the right to receive shares in OncoZenge shall be February 5, 2021.

Key Points: 
  • Today, the Board of Moberg Pharma has decided that the record date for the right to receive shares in OncoZenge shall be February 5, 2021.
  • The Board of Directors of Moberg Pharma has decided that the record date for the right to receive shares in OncoZenge shall be February 5, 2021.
  • Ten (10) ordinary shares in Moberg Pharma, as of the record date for the distribution, entitle to one (1) share in OncoZenge.
  • The record date for the right to participate in the Rights Issue is February 17, 2021.

Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in OncoZenge

Retrieved on: 
Monday, November 30, 2020
Moberg, Income tax in the United States, Share, Tax, Income tax

STOCKHOLM, Nov. 30, 2020 /PRNewswire/ --Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has obtained a positive decision confirming that the Swedish Tax Agency shares the Company's assessment that the Company's proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act, which means that the distribution will not be subject to taxation for the Company's shareholders.

Key Points: 
  • STOCKHOLM, Nov. 30, 2020 /PRNewswire/ --Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has obtained a positive decision confirming that the Swedish Tax Agency shares the Company's assessment that the Company's proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act, which means that the distribution will not be subject to taxation for the Company's shareholders.
  • The board of directors of Moberg Pharma has proposed that the extraordinary general meeting to be held tomorrow, 1December 2020, approves to distribute all of the Company's shares in the subsidiary OncoZenge through a Lex Asea distribution with a contemplated record date in January/February 2021.
  • The Company now has a obtained a decision confirming that the Swedish Tax Agency shares the Company's assessment that the Company's proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act with, which means that the distribution will not be subject to taxation for Moberg Pharma's shareholders.

Invitation to market update in Moberg Pharma on November 25th

Retrieved on: 
Monday, November 23, 2020
Moberg

STOCKHOLM, Nov. 23, 2020 /PRNewswire/ --On November 25th, 2020, at 02:00 am (CET), investors, analysts and journalists are invited to participate in a digital company presentation.

Key Points: 
  • STOCKHOLM, Nov. 23, 2020 /PRNewswire/ --On November 25th, 2020, at 02:00 am (CET), investors, analysts and journalists are invited to participate in a digital company presentation.
  • Moberg pharma recently announced its intention to distribute its subsidiary OncoZenge through a Lex ASEA distribution before listing the company on Nasdaq First North Growth Market, as well as securing financing both for OncoZenge and Moberg Pharma.
  • The teleconference will be hosted by Moberg Pharmas's CEO Anna Ljung and Chairman of the Board Peter Wolpert.
  • To participate in the conference, please use the following link:

OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing

Retrieved on: 
Monday, November 16, 2020
Financial markets, Erik Penser, Stockbrokers, SEK, Moberg, Stock dilution

The capital requirement to finance the Phase 3 study, expected to begin in early 2022, and the Company's continuing operations is approximately SEK 60 million.

Key Points: 
  • The capital requirement to finance the Phase 3 study, expected to begin in early 2022, and the Company's continuing operations is approximately SEK 60 million.
  • To secure its initial capital requirements, OncoZenge has received binding commitments for a directed issue of approximately SEK 10 million ("Directed Issue").
  • Based on the subscription price in the Directed Issue, the value of OncoZenge before the Directed Issue is approximately SEK 50 million, resulting in a dilution of approximately 16.7 percent from the Directed Issue.
  • Erik Penser Bank is serving as financial advisor and Gernandt & Danielsson Advokatbyr is serving as legal advisor to Moberg Pharma and OncoZenge in connection with the distribution, financing and listing of OncoZenge.

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million

Retrieved on: 
Friday, November 6, 2020
Nasdaq Nordic, SEK, Moberg

STOCKHOLM, Nov. 6, 2020 /PRNewswire/ -- The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs.

Key Points: 
  • STOCKHOLM, Nov. 6, 2020 /PRNewswire/ -- The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs.
  • The Rights Issue comprises Units and will provide Moberg Pharma with proceeds of approximately SEK 150 million before transaction costs.
  • The Rights Issue is comprised by approximately forty-two (42) percent subscription commitments and of approximately fifty-eight (58) percent issue guarantees.
  • The Rights Issue is comprised of approximately forty-two (42) percent subscription commitments and of approximately fifty-eight (58) percent issue guarantees.